Radiopharmaceutical Market Size Projected to Reach $17.48 billion by 2034 | 9.9%

According to Straits Research the global radiopharmaceutical market size was valued at $7.47 billion in 2025 and is projected to grow from $8.21 billion in 2026 to $17.48 billion by 2034, registering a CAGR of 9.9% during the forecast period (2026–2034).

Radiopharmaceuticals are specialized radioactive compounds used in medical imaging and targeted therapy. These drugs play a crucial role in diagnosing and treating various conditions, particularly cancer, cardiovascular diseases, and neurological disorders. Radiopharmaceuticals enable precise disease localization and monitoring by emitting radiation that is detectable by imaging systems such as PET and SPECT scans. Moreover, therapeutic radiopharmaceuticals deliver targeted radiation to diseased cells, minimizing damage to healthy tissues.

Market Dynamics

Government investments and regulatory approvals drive the global market

Governments across the globe are crucial drivers in advancing the global radiopharmaceutical industry, providing significant investments, regulatory approvals, and funding for nuclear medicine research and infrastructure. These efforts not only spur innovation but also help overcome critical supply chain challenges, especially for short-lived radioisotopes that are vital for both diagnostic and therapeutic applications.

• For instance, in October 2023, India’s Department of Atomic Energy (DAE) announced an investment of ₹250 crore to establish a dedicated nuclear reactor under a Public-Private Partnership model. This project is aimed at increasing the production of Molybdenum-99 (99Mo), a crucial precursor for Technetium-99m (99mTc)-based gamma imaging, which will help alleviate the ongoing global shortage of this essential isotope.

Integration of artificial intelligence creates tremendous opportunities

The incorporation of artificial intelligence into radiopharmaceuticals is transforming drug discovery, development, and clinical applications. AI enhances target selection, optimizes imaging accuracy, and streamlines production processes, driving efficiencies across the sector. AI-driven models aid in the design of radiotracers, accelerating the identification of novel compounds and significantly reducing research time and costs.

• For example, a study published in PET Clinics in October 2021 highlights the transformative potential of AI in the development of diagnostic and therapeutic radiopharmaceuticals. The authors discuss how artificial intelligence-based in silico computational modeling can accelerate the design and optimization of radiopharmaceuticals by predicting molecular interactions, pharmacokinetics, and toxicity profiles.

Regional Analysis

North America holds the largest share in the global radiopharmaceuticals market, driven by its well-established healthcare infrastructure, significant investments in nuclear medicine research, and the presence of leading pharmaceutical and biotechnology companies. The region benefits from supportive regulatory frameworks that streamline radiopharmaceutical approvals and usage, fostering continuous innovation. Moreover, the high prevalence of chronic diseases, including cancer and cardiovascular disorders, has amplified the demand for advanced diagnostic and therapeutic radiopharmaceuticals.

Market Segments

1. By Radioisotopes Type
   1. Technetium 99
   2. Fluorine 18
   3. Iodine 131
   4. Lutetium 177
   5. Yttrium 90
   6. Radium-223
   7. Others
2. By Applications
   1. Diagnostics 
   2. Therapeutics
3. By Source
   1. Cyclotrons
   2. Nuclear Reactors
   3. Others
4. By End-User
   1. Hospitals
   2. Medical Imaging Centers
   3. Cancer Research Institute
   4. Others
5. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Central & South America
   5. The Middle East and Africa